Clinical Trial Update: Study of MLN8237 in Participants With Advanced Hematological Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of MLN8237 in advanced hematological malignancies completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• B-cell Chronic Lymphocytic Leukemia
• B-cell Follicular Lymphoma
• B-cell Mantle Cell Lymphoma
• B-cell Marginal Zone Lymphoma
• B-cell Small Lymphocytic Lymphoma
• Diffuse Large B-cell Lymphoma
• Enteropathy-associated T-cell Lymphoma
• Multiple Myeloma
• Nk Lymphoma
• Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified
• Waldenström Macroglobulinemia

Drugs mentioned

• MLN8237 (alisertib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2019-05-31